Free tool
FAERS Monitor: Plegridy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125499 or its brand name (Plegridy, Peginterferon Beta-1a). Reports on generic versions are filed under their own applications.
Reports
13,098
Serious
5,630
43% of reports
Hospitalization
3,151
Death reported
336
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- influenza like illness1,470
- injection site erythema1,065
- multiple sclerosis relapse979
- fatigue715
- headache619
- pain609
- injection site reaction580
- device malfunction572
- multiple sclerosis566
- pyrexia522
- memory impairment474
- malaise471
- drug delivery system malfunction468
- injection site pain451
- fall439
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 18 |
| 2015 | 646 |
| 2016 | 2,699 |
| 2017 | 1,997 |
| 2018 | 1,831 |
| 2019 | 1,326 |
| 2020 | 1,077 |
| 2021 | 919 |
| 2022 | 808 |
| 2023 | 610 |
| 2024 | 463 |
| 2025 | 465 |
| 2026 | 238 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,061 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug delivery system malfunctionSignal | 468 | 161.7 | 147.3 | 67,783 |
| influenza like illnessSignal | 1,470 | 29.2 | 27.8 | 39,424 |
| multiple sclerosis relapseSignal | 979 | 23.3 | 21.9 | 20,599 |
| multiple sclerosisSignal | 566 | 19.2 | 17.7 | 9,666 |
| injection site erythemaSignal | 1,065 | 13.9 | 13.1 | 12,700 |
| injection site reactionSignal | 580 | 13.6 | 12.6 | 6,747 |
| device malfunctionSignal | 572 | 13.2 | 12.2 | 6,390 |
| memory impairmentSignal | 474 | 5.6 | 5.1 | 1,772 |
| pyrexiaSignal | 522 | 2.4 | 2.2 | 442 |
| injection site painSignal | 451 | 2.4 | 2.2 | 358 |
| fallSignal | 439 | 2.1 | 1.9 | 262 |
| malaise | 471 | 1.7 | 1.6 | 146 |
| pain | 609 | 1.6 | 1.5 | 138 |
| headache | 619 | 1.6 | 1.5 | 137 |
| fatigue | 715 | 1.5 | 1.4 | 113 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.